IQVIA (IQV) Expected to Release Quarterly Earnings on Tuesday

IQVIA (NYSE:IQV) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect IQVIA to announce earnings of $3.02 per share and revenue of $4.3020 billion for the quarter. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the company posted $2.70 earnings per share. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. On average, analysts expect IQVIA to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.

IQVIA Trading Up 0.1%

NYSE:IQV opened at $208.22 on Monday. The company has a market cap of $34.75 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50 day simple moving average of $188.23 and a two-hundred day simple moving average of $187.05. IQVIA has a 12 month low of $154.50 and a 12 month high of $247.04.

IQVIA declared that its board has authorized a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Mizuho upped their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. HSBC reissued a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Evercore restated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Finally, Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $225.71.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently bought and sold shares of IQV. Brighton Jones LLC lifted its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC increased its position in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of IQVIA in the second quarter worth about $514,000. First Trust Advisors LP raised its stake in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC lifted its position in shares of IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.